In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Arava (Sanofi-Aventis)
- INDICATIONS: Rheumatoid arthritis
- CLASS: Disease-modifying antirheumatic drug (DMARD), Tyrosine kinase inhibitor
- HALF-LIFE: 14–15 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alefacept, Azacitidine, BCG Vaccine, Betamethasone, Cabazitaxel, Carvedilol, Cholestyramine(unless drug elimination required), CYP2C9 substrates, Denileukin, Denosumab, Docetaxel, Echinacea, Fingolimod, Gefitinib, Immunosuppressants, Lenalidomide, Live vaccines, Methotrexate, Natalizumab, Oxaliplatin, Pazopanib, Pemetrexed, Phenytoin, Pimecrolimus, Pralatrexate, Pralatrexate, Rifampin, Tacrolimus, Temsirolimus, Teriflunomide, Tolbutamide, Trastuzumab, Triamcinolone, Typhoid Vaccine, Vitamin K antagonists, Warfarin, Yellow Fever Vaccine
- See adverse reactions attributed to class:
Investigated for treating COVID-19.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of leflunomide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/30/2025
